Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026

Profusa, Inc.

EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.
US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.
Estimates 35% European population coverage through intended distribution channels.
Targets $10.5B tissue oxygen market and >500M glucose monitoring population.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-103772
form_type: 8-K
ticker: PFSA
cik: 0001859807
company_name: Profusa, Inc.
filed_at: 2025-10-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.851751+00:00
generated_at: 2026-05-17T01:25:00.223123+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-103772
json_url: https://secwatch.observer/filing/0001213900-25-103772.json
markdown_url: https://secwatch.observer/filing/0001213900-25-103772.md
text_url: https://secwatch.observer/filing/0001213900-25-103772.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/0001213900-25-103772-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/ea0263091-8k_profusa.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-103772

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.